Pathophilia

Posted by bmartin on Jan 30, 2019 in Neurology

Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for...

Posted by bmartin on Sep 19, 2016 in FDA, Neurology, Pediatrics, Pharma

This morning the FDA announced its approval of eteplirsen (brand name, Exonys 51) for the treatment of...

The annual costs of disease-modifying therapies (DMTs) for multiple sclerosis (MS) have increased at...

Posted by bmartin on Mar 30, 2015 in Ethics, Neurology, Pharma

Gabrielle Strobel‘s comprehensive coverage of the phase 1 study of Biogen’s aducanumab, its...

Posted by bmartin on Mar 23, 2015 in Media, Neurology, Pharma

Last week, the NYT, WSJ, and Wall Street reacted enthusiastically, if not irrationally, to results of a...

Posted by bmartin on Mar 11, 2015 in Neurology, Pharma

Sometime in early January, I starting wondering about the status of TRx0237 (aka methylthioninium chloride...

New Book – Coming Soon!